RxDoctor Payments Data

Thomas Hogan, MD

Hematology & Oncology · Morgantown, WVNPI 1366555922

Payments from drug & device makers

What this record shows

This record is dominated by education: $300 of the $480 with a category attached, or 62.5%. 7 manufacturers reported payments, led by Sumitomo Pharma America, Inc. at 24.2% of the total. That places this record below the midpoint for hematology & oncology clinicians in WV, where the typical reported total is $1,186.

$480in general payments, 2019–2025

Across 12 payments — averaging $40.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$116
  • Seagen Inc.$100
  • Sobi, Inc$100
  • Pfizer$74
  • Novartis$45
  • Myovant Sciences Inc.$24
  • plus $21 from 1 others
$44,347in research payments, 2019–2025

Across 70 payments — averaging $633.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Incyte Corporation$44K

What the payments were for

  • Food & beverage$18037%
  • Education$30063%

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$480 in reported general payments places this provider in the 40th percentile of 72 hematology & oncology providers in West Virginia.

See all hematology & oncology providers in West Virginia

Medicare billing

Part B allowed, 2024
$39,433
Medicare patients
121
Services billed
410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate21$527,631
Abiraterone Acetate172$516,072
XtandiEnzalutamide38$447,793
NubeqaDarolutamide31$355,038
ZytigaAbiraterone Acetate18$200,440
OrgovyxRelugolix21$53,053
XareltoRivaroxaban18$17,788
Bicalutamide36$903
Prednisone172$782
Ondansetron Hcl54$659
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen35$598
Oxycodone Hcl30$589
Morphine Sulfate ErMorphine Sulfate18$293
Gabapentin15$257
Tamsulosin Hcl12$180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx$116$53,05321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 72 hematology & oncology providers in West Virginia.

Other hematology & oncology in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →